echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > 50 billion pharmaceutical "white horse" set to increase growth change "package field" of high capital or out?

    50 billion pharmaceutical "white horse" set to increase growth change "package field" of high capital or out?

    • Last Update: 2020-08-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    In the pharmaceutical circle frequently shot high-rise capital is once again painted screen.
    just seems a little different this time. On the evening of July 22,
    , Caley Inn (Securities Code: 002821. SZ) issued a notice that, in view of the current changes in the capital market environment, and take into account the company's actual situation, development planning and many other factors, the previously issued plan to adjust.
    this is the focus of this is that the previous package of Kelley Yingding's increase in high-rise capital, from exclusive war investment to "issued to no more than 35 specific investors."
    and in February, Gaoyu Capital with a total of 2.3 billion yuan (123.56 yuan per share price) to package the current fixed increase in Kelley Inn, to become the sole subscriber.
    based on today's latest closing price of 234 yuan per share, this must be more than 2 billion yuan to subscribe to "floating profit".
    five months apart, the feast was ruined by a paper announcement.
    01 What happened in the last five months? On the evening of February 14th, the CSRC issued three heavyweight documents in a row, and the new refinancing rules officially landed.
    the new rules give a lot of preferential policies, including listed companies to introduce non-public issues of strategic investors, you can enjoy the lock price issue, the issue price of 20% discount, the lock period halved.
    quick-response Ofthea Kelley is the first listed company to "eat crab" under the new rules.
    just two days after the new rules were issued, Kailaiin quickly disclosed the announcement of a non-public offering of shares, the proposed non-public offering of no more than 18.7 million shares, the issue price of 123.56 yuan / share, the total amount of capital raised not more than 2.311 billion yuan.
    and GaoYing Capital at a discount of 2percent to the price of Kelenet fixed increase, fixed increase after the completion of its ownership of more than 5% of Kelley Inn shareholders.
    as the world's leading provider of CDMO solutions, Kelelion is dedicated to technological innovation and commercial applications of pharmaceutical processes worldwide.
    it is understood that, according to the original plan, after the completion of the fixed increase in the issue, Kailaiin will invest in gaoying capital and its related parties to invest in innovative pharmaceutical companies to provide high-quality CMC research and development and production services, Gaoyu Capital will also rely on its own resource advantages to actively promote Kelein to enhance the breadth and depth of service innovative pharmaceutical companies.
    in response to this investment intentions, Gao Yau Capital also made it clear: strategic investment, and access to stock appreciation gains.
    capital markets are happy to pay for it.
    the day after the announcement, Kelley's share price rose and went up, and since then it has risen all the way up, as of today's close, its share price has risen to 234 yuan / share, up as much as 89%.
    just interesting, in terms of the increase itself, the news in the five-month period has been delayed, until the previous "set increase program adjustment" announcement appeared.
    but things have changed.
    comparison before and after the two announcements can be found that the fixed increase program adjustment is quite a lot, the target, lock out period and pricing benchmark date and other key information have changed.
    the object of the issue and the mode of subscription in the issue object, before GaoGao Capital is the only subscription object, through cash to subscribe for the entire non-public offering.
    adjusted to become, "This non-public offering is for no more than 35 specific investors."
    " issue price and pricing have also changed.
    previous announcement, the issue share price is 123.56 yuan / share, the pricing benchmark date is the date of the announcement of the increase plan, the issue price is not less than 80% of the average price of the company's stock trading in the 20 trading days prior to the pricing benchmark date.
    revised, Kelelion did not directly specify the issue price, but instead changed to market pricing, the pricing base date as the first day of the issue period.
    the limited sale period was changed from 18 months to 6 months, during which time the subscribed shares may not be transferred or traded.
    the amount of funds raised and the amount of funds to be raised in this adjustment has not changed, still 231,057.20 million yuan.
    but the use of fund-raising from "full replenishment of the company's working capital", changed to specific projects, including wholly-owned Sun's innovative drug service platform expansion project, biomolecular innovative drugs and preparations research and development and production platform construction projects, innovative drug CDMO production base construction projects, the remaining 660 million yuan for supplementary working capital.
    02 set to increase the "change" far more than The Kelley in fact, the target "from 1 to 35" is not the only Kelley in the family.
    7 and 14, the same drug research and development outsourcing track of the drug stone technology (securities code: 300725. SZ also announced that it had terminated its February non-public offering of shares (planning an additional $650 million raising) and announced a new plan to increase it.
    similar to Kelelion, the new plan adjustment of Pharmaceutical Stone Technology includes the issuance target from "Xingquan Fund" to "no more than 35 specific investors";
    on the same day to adjust the plan is also Kangchen Pharmaceuticals (securities code: 603590. SH).
    before April 21, Kangchen Pharmaceuticals has announced that the proposed capital raising of not more than 400 million yuan, the issue of Kangchen Pharmaceuticals, one of the actual controllers Wang Xixuan, the company's first employee shareholding plan. On July 14,
    , Kangchen Pharmaceuticals announced the end of this certain increase program, and in the new scheme, the target of the increase into one of the company's actual controllers, Wang Xixuan and CBC investment.
    "In view of regulatory policies and changes in the capital market environment and the company's current situation, the Company has decided, after careful consideration, to terminate the previous non-public offering of A-shares."
    ", "This is the official explanation given by Kangchen Pharmaceuticals for the adjustment. what is the real reason behind the
    's addition plan and object "change to the end"? In this regard, some people noted that "the current market does have the regulatory layer on the new refinancing rules of strategic investors tightening news", but also insiders understand that "the regulatory layer does not support the introduction of strategic investors lock-price issuance behavior."
    "We are also concerned about the movement of these companies, but at present has not received notice to withdraw the material," said a staff member of a listed company waiting for additional approval in an interview with the media.
    " this also means that the new rules after the market to increase the next trend, still has time to verify, but the market, especially listed companies will undoubtedly maintain a high degree of concern.
    after all, according to statistics, since February 14 thinly imposed new rules, more than 180 companies have issued refinancing plans, including nearly 100 companies to the way to lock-up.
    articles from Sina Finance, China Entrepreneurs Magazine, Delin Society and so on.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.